A possible role for vaccination in the treatment of psoriasis?

Giornale Italiano di Dermatologia e Venereologia

Volumn 143, Issue 2, 2008, Pages 105-117

  Baker, B S ^a   Powles, A V ^a   Fry, L ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Faculty of Medicine Imperial College St Mary's Campus ^*  (United Kingdom)

Author keywords

Psoriasis; Streptococcal vaccines; Vaccination

Indexed keywords

BACTERIAL VACCINE; CORTICOSTEROID; CYCLOSPORIN; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; PEPTIDE VACCINE;

CANDIDA ALBICANS; DISEASE ASSOCIATION; DISEASE EXACERBATION; GENE LOCUS; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INNATE IMMUNITY; MALASSEZIA; NONHUMAN; PSORIASIS; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; T LYMPHOCYTE; TINEA; UNSPECIFIED SIDE EFFECT; WART VIRUS;

EID: 45749129131     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Baker BS. Skin Immune Mechanisms in Health and Disease. UK: Garner Press; 2006.
2. Mallon E, Bunce M, Wojnarowska F, Welsh K. HLA-CW*0602 is a susceptibility factor in type I psoriasis, and evidence Ala-73 is increased in male type I psoriatics. J Invest Dermatol 1998;109:183-6.
3. Hensler T, Christophers E. Psoriasis of early and late onset: Characteristics of two types of psoriasis. J Am Acad Dermatol 1985;13:450-56.
4. Gudjonsson J, Karason A, Antonsdottir A, Runarsdottir EH, Gulcher JR, Stefansson K et al. HLA-Cw6 positive and HLA-Cw6 negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol 2002;118:362-5.
5. Fry L, Powles AV, Corcoran S, Rogers S, Ward J, Unsworth DJ. HLA Cw*06 is not essential for streptococcal-induced psoriasis. Br J Dermatol 2006;154:850-3.
6. Baker BS, Ovigne JM, Fischetti VA, Powles AV, Fry L. Reduced gamma IFN responses associated with HLA-DR15 presentation of streptococcal cell wall proteins to dermal Th1 cells in psoriasis. J Clin Immunol 2003;23:407-15.
7. Jullien D, Barker JN. Genetics of psoriasis. J Eur Acad Dermatol Venereol 2006;20(Suppl 2):42-51.
8. Asumalahti K, Ameen M, Suomela S, Hagforsen E, Michaëlsson G. Evans J et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 2003;120:627-32.
9. Allen MH, Ameen H Veal C, Evans J, Ramrakha-Jones VS, Marsland AM et al. The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. J Invest Dermatol 2005;124:103-6.
10. Bowcock AM, Cookson WO. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet 2004;13(Review Issue 1):R43-55.
11. Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch S et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility I gene. Am J Hum Genet 2006;78:827-51.
12. Helms C, Cao L, Krueger JG, Wijsman EM, Chamion F, Gordon D et al. A putative RUNXI binding site variant between SLC9A3RI and NAT9 is associated with susceptibility in psoriasis. Nat Genet 2003;35:349-56.
13. Hewett D, Samuelsson L, Polding I, Enlund F, Smart D, Cantone K et al. Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localised single nucleotide polymorphism map. Genomics 2002;79:305-14.
14. Zenz R, Efert R, Kerner L, Florin L, Hummerich L, Mehic D et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005;437:369-75.
15. Lu X, Wang M, Qi J, Wang H, Li X, Gupta D et al. Peptidoglycan recognition proteins are a new class of human bactericidal proteins. J Biol Chem 2006;281:5895-907.
16. Sun C, Mathur P, Dupuis J, Tizard R, Ticho B, Crowell T et al. Peptidoglycan recognition proteins Pglyrp-3 and Pglyrp-4 are encoded from the Epidermal Differentiation Complex and are candidates for PSORS4 locus on chromosome 1q21. Hum Genet 2006;119:113-25.
17. Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol 2007;25:606-15.
18. Norrlind R. Significance of infections in origin of psoriasis. Acta Rheumatol Scand 1955;1:135-44.
19. Cohen-Tervaert WC, Esseveld HA. A study of the incidence of haemolytic streptococci in the throat in patients with psoriasis with reference to their role in the pathogenesis of the disease. Dermatologica 1970;140:282-90.
20. Belew PW, Wannamaker LW, Johnson D, Rosenberg EW. Beta haemolytic streptococcal types associated with psoriasis. In: Kimera K, Kotanie S, Shiokawa Y, editors. Recent advances of streptococcal diseases. UK: Reedbooks Ltd; 1985. p. 334.
21. Telfer NR, Chalmers RJG, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992;128:39-42.
22. Tervaert WC, Esseveld H. A study of the incidence of haemolytic streptococci in the throat in patients with psoriasis vulgaris, with reference to their role in the pathogenesis of the disease. Dermatologica 1970;140:282-90.
23. Wardrop P, Weller R, Marais J, Kavanagh G. Tonsillitis and chronic psoriasis. Clin Otolaryngol 1998;23:67-8.
24. Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B, Kristinsson KG, Valdimarsson H. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Brit J Dermatol 2003;149:530-4.
25. Osterlund A, Popa R, Nikkila T, Scheynius A, Engstrand L. Intracellular reservoir of Streptococcus pyogenes in vivo: a possible explanation for recurrent pharyngotonsillitis. Laryngoscope 1997;107:640-7.
26. Molinari G, Chhatwal GS. Streptococcal invasion. Curr Opin Microbiol 1999;2:56-61.
27. Nyfors A, Rasmussen PA, Lemholt K, Eriksen B. Improvement of recalcitrant psoriasis vulgaris after tonsillectomy. J Laryngol Otol 1976;90:789-94.
28. Hone SW, Donnelly MJ, Powell F, Blayney AW. Clearance of recalcitrant psoriasis after tonsillectomy. Clin Otolaryngol 1996;21:546-7.
29. Rantakokko K, Rimpilainen M, Uksila J, Jansen C, Luukkainen R, Toivanen P. Antibodies to streptococcal cell wall in psoriatic arthritis and cutaneous psoriasis. Clin Exp Rheumatol 1997;15:399-404.
30. Weisenseel P, Prinz JC. Incidental detection of S.pyogenes-DNA in psoriatic skin by PCR. Arch Dermatol Res 2005;296:573-6.
31. Honig PJ. Guttate psoriasis associated with perianal streptococcal disease. J Paediatr 1988;113:1037-9.
32. Leung DY, Gately M, Trumble A, Ferguson-Darnell B, Schlievert PM, Picker LJ. Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin-12 production. J Exp Med 1995;181:747-53.
33. Leung DY, Travers JB, Giorno R, Norris DA, Skinner R, Aelion J et al. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest 1995;96:2106-12.
34. Menssen A, Trommler P, Vollmer S, Schendel D, Albert E, Gürtler L et al. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol 1995;155:4078-83.
35. Diluvio L, Vollmer S, Besqen P, Ellwart JW, Chimenti S, Prinz JC. Identical T-cell receptor β-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. J Immunol 2006;176:1704-11.
36. Baker BS, Fry L. A role for peptidoglycan in psoriasis? Giornale Ital Dermatol Venereol 2008. In Press.
37. Brown DW, Baker BS, Ovigne J-M, Hardman C, Powles AV, Fry L. Skin CD4+ T cells produce interferon-gamma in vitro in response to streptococcal antigens in chronic plaque psoriasis. J Invest Dermatol 2000;114:576-80.
38. Brown DW, Baker BS, Ovigne J-M, Fischetti VA, Hartman C, Powles AV et al. Non-M protein on the cell wall and membrane of group A streptococci induces IFN-y production by dermal CD4+ T cells in psoriasis. Arch Dermatol Res 2001;293:165-70.
39. Baker BS, Ovigne J-M, Fischetti VA, Powles A, Fry L. Selective response of dermal Th-1 cells to 20-50 kDa streptococcal cell wall proteins in chronic plaque psoriasis. Scand J Immunol 2003;58:335-41.
40. Gudmundsdottir AS, Sigmundsdottir H, Sigurgeirsson B, Good MF, Valdimarsson H, Jonsdottir I. Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis? Clin Exp Immunol 1999;117:580-6.
41. Johnston A, Gudjonsson JE, Sigmundsdottir H, Love TJ, Valdimarsson H. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8+T cells. Clin Exp Immunol 2004;138:83-93.
42. Baker BS, Laman JD, Powles AV, van der Fits L, Voerman JSA, Melief M-J et al. Peptidoglycan and peptidoglycan-specific Th-1 cells in psoriasis. J Pathol 2006;209:174-81.
43. Boneca IG. The role of peptidoglycan in pathogenesis. Curr Opin Microbiol 2005;8:46-53.
44. Osterlund A, Popa R, Nikkila T, Scheynius A, Engstrand L. Intracellular reservoir of Streptococcus pyogenes in vivo: a possible explanation for recurrent pharyngotonsillitis. Laryngoscope 1997;107:640-7.
45. Mcmillin DL, Richards DG, Mein EA, Nelson CD. Systemic aspects of psoriasis : an integrative model based on intestinal etiology. Integrative Med 2000;2:105-13.
46. Klasen IS, Melief MJ, van Halteren AG, Schouten WR, van Blankenstein M, Hoke G et al. The presence of peptidoglycan-polysaccharide complexes in the bowel wall and the cellular responses to these complexes in Crohn's disease. Clin Immunol Immunopathol 1994;71:303-8.
47. Schrijver IA, Melief MJ, Tak PR Hazenberg MP, Laman JD. Antigen-presenting cells containing bacterial peptidoglycan in synovial tissues of rheumatoid arthritis patients coexpress costimulatory molecules and cytokines. Arthritis Rheum 2000;43:2160-8.
48. Schrijver IA, van Meurs M, Melief MJ, Wim Ang C, Bulievac D, Ravid R et al. Bacterial peptidoglycan and immune reactivity in the central nervous system in multiple sclerosis. Brain 2001;124:1544-54.
49. Baker BS, Brown DW, Fischetti VA, Ovigne JM, Porter W, Powles A et al. Skin T cell proliferative response to M protein and other cell wall and membrane proteins of group A streptococci in chronic plaque psoriasis. Clin Exp Immunol 2001;124:516-21.
50. Leung DY, Harbeck R, Bina P, Reiser RF, Yang E, Norris DA et al. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest 1993;92:1374-80.
51. Tomi NS, Kränke B, Aberer E. Staphylococcal toxins in patients with psoriasis, atopic dermatitis and erythroderma, and in healthy control subjects. J Am Acad Dermatol 2005;53:67-72.
52. Farr PM, Krause LB, Marks JM, Shuster S. Response of scalp psoriasis to oral ketoconazole. Lancet 1985;2:921-2.
53. Rosenberg EW, Belew PW. Improvement of psoriasis of the scalp with ketoconazole. Arch Dermatol 1982;118:370-1.
54. Lober CW, Belew PW, Rosenberg EW, Bale G. Patch tests with killed sonicated microflora in patients with psoriasis. Arch Dermatol 1982;118:322-5.
55. Mathov I, Plotkin L, Abatangelo C, Galimberti R, Squiquera L, Leoni J. Antibodies from patients with psoriasis recognise N-acetyl-glucosamine terminals in glycoproteins from Pityriasis ovale. Clin Exp Immunol 1996;105:79-83.
56. Baker BS, Powles AV, Garioch JJ, Hardman C, Fry L. Differential reactivity to the round and oval forms of Pityrosporum in the skin of patients with psoriasis. Brit J Dermatol 1997;136:319-25.
57. Bunse T, Mahrle G. Soluble Pityrosporum-derived chemoattractant for polymorphonuclear leukocytes of psoriatic patients. Acta Derm Venereol 1996;76:10-2.
58. Baroni A, Paoletti I, Ruocco E, Agozzino M, Tufano MA, Donnarumma G. Possible role of Malassezia furfur in psoriasis: modulations of TGF-b1, integrin and HSP70 expression in human keratinocytes and in the skin of psoriasis-affected patients. J Cutan Pathol 2004;31:35-42.
59. Baroni A, Orlando M, Donnarumma A, Farro P, Iovene MR, Tufano MA et al. Toll-like receptor 2 (TLR-2) mediates intracellular signalling in human keratinocytes in response to Malessezia furfur. Arch Derm Res 2006;297:280-8.
60. Buslau M, Menzel I, Holzmann H. Fungal flora of human faeces in psoriasis and atopic dermatitis. Mycoses 1990;33:90-4.
61. Sneff H, Bothe C, Busacker J. Studies on the yeast flora in patients suffering from psoriasis capillitii or seborrheic dermatitis of the scalp. Mycoses 1990;33:29-32.
62. Waldman A, Gilhar A, Duek L , Berdicevsky I. Incidence of Candida in psoriasis - a study on the fungal flora of psoriatic patients. Mycoses 2001;44:77-81.
63. Buslau M, Hanel H, Holzman H. The significance of yeasts in seborrheic dermatitis. Hautarzt 1989;40:611-3.
64. Walsh R Norris DA, Abe J, Martin DK, Giorno R, Leung DY. Candida albicans induces selective expansion of human T lymphocytes expressing the T-cell receptor variable region V beta 5.1. J Dermatol Sci 1996;12:140-6.
65. Favre M, Orth G, Majewski S, Baloul S, Pura A, Jablonska S. Psoriasis: a possible reservoir for human papillomavirus type 5, the virus associated with skin carcinomas of epidermodysplasia verruciformis. J Invest Dermatol 1998;110:311-7.
66. Ramoz N, Rueda LA, Bouadjar B, Favre M, Orth G. A susceptibility locus for epidermodysplasia verruciformis, an abnormal predisposition to infection with the oncogenic human papillomavirus type 5, maps to chromosome 17 qter in a region containing a psoriasis locus. J Invest Dermatol 1999;112:259-63.
67. Majewski S, Favre M, Orth G, Jablonska S. Is human papillomavirus type 5 the putative autoantigen involved in psoriasis? J Invest Dermatol 1998;111:541-2.
68. Vittorio Luigi De Socio G, Simonetti S, Stagni G. Clinical improvement of psoriasis in an AIDS patient effectively treated with combination antiretroviral therapy. Scand J Infect Dis 2006;38:74-5.
69. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006;54:567-80.
70. Bos JD, de Rie MA, Teunissen MBM, Piskin G. Psoriasis: dysregulation of innate immunity. Brit J Dermatol 2005;152:1098-107.
71. Girardin SE, Boneca IG, Carneiro LA, Antignac A, Jehanno M, Viala J et al. Nodi detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 2003;300:1584-7.
72. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003;278:8869-72.
73. Girardin SE, Hugot JP, Sansonetti PJ. Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. Trends Immunol 2003;24:652-8.
74. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 1990;85:962-3.
75. International Psoriasis Genetics Consortium. The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs. Am J Hum Genet 2003;73:430-7.
76. Borgiani P, Vallo L, D'Apice MR, Giardina E, Pucci S, Capon F et al. Exclusion of CARD 15/NOD2 as a candidate susceptibility gene to psoriasis in the Italian population. Eur J Dermatol 2002;12:540-2.
77. Lascorz J, Burkhardt H, HuffmeierU, Böhm B, Schurmeyer-Horst F, Lohmann J et al. Lack of genetic association of the three more common polymorphisms of CARD15 with psoriatic arthritis and psoriasis in a German cohort. Ann Rheum Dis 2005;64:951-4.
78. Ho P, Bruce IN, Silman A, Symmons D, Newman B, Young H et al. Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum 2005;52:3596-602.
79. Rahman P, Bartlett S, Siannis F, Pellett FJ, Farewell VT, Peddle L et al. CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am J Hum Genet 2003;73:677-81.
80. Voss E, Wehkamp J, Wehkamp K, Stange EF, Schröder JM, Harder J. NOD2/CARD15 mediates induction of the anti-microbial peptide human beta-defensin-2. J Biol Chem 2006;281:2005-11.
81. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. New Engl J Med 2002;347:1151-60.
82. Harder J, Bartels J, Christophers E, Schroder J-M. Isolation and characterisation of human b-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001;276:5707-13.
83. Joly S, Organ CC, Johnson GK, McCray PB Jr, Guthmiller JM. Mol Immunol 2005;42:1073-84.
84. Hollox EJ, Huffmeier U, Zeeuwen PLJM, Palla R, Lascorz J, Rodijk-Olthuis D et al. Psoriasis is associated with increased b-defensin geneomic copy number. Nat Genet 2008;40:23-5.
85. Capon F, Semprini S, Chimenti S, Fabrizi G, Zambruno G, Murgia S et al. Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. J Invest Dermatol 2001;116:728-30.
86. Lee YA, Ruschendorf F, Windemuth C, Schmitt-Egenolf M, Stadelmann A, Nurnberg G et al. Genomewide scan in German families reveals evidence for a novel psoriasis-susceptibility locus on chromosome 19p13. Am J Hum Genet 2000;67:1020-4.
87. Sun C, Mathur P, Dupuis J, Tizard R, Ticho B, Crowell T et al. Peptidoglycan recognition proteins Pglyrp3 and Pglyrp4 are encoded from the Epidermal Differentiation Complex and are candidate genes for the Psors4 locus on chromosome 1 q21. Hum Genet 2006;119:113-25.
88. Lu X, Wang M, Qi J, Wang H, Li X, Gupta D et al. Peptidoglycan recognition proteins are a new class of human bactericidal proteins. J Biol Chem 2006;281:5895-907.
89. Cho JH, Fraser IP, Fukase K, Kusumoto S, Fujimoto Y, Stahl GL et al. Human peptidoglycan recognition protein S is an effector of neutrophil-mediated innate immunity. Blood 2005;106:2551-8.
90. Wang ZM, Li X, Cocklin RR, Wang M, Wang M, Fukase K et al. Human peptidoglycan recognition protein-L is an N-acetylmuramoyl-L-alanine amidase. J Biol Chem 2003;278:49044-52.
91. Baker BS, Swain AF, Griffiths CEM, Leonard JN, Fry L, Valdimarsson H. Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: the effects of PUVA treatment. Clin Exp Immunol 1985;61:526-34.
92. + T cells induces psoriasis. Am J Pathol 1999;155:145-58.
93. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB et al. Response of psoriasis to a lymphocyte-selective toxin (DAB3ggIL-2) suggests a primary immune, but not keratinocyte. pathogenic basis. Nat Med 1995;1:442-7.
94. H17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445:648-51.
95. Griffiths CEM, Voorhees JJ, Nickoloff BJ. Characterisation of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 1989;20:617-29.
96. Giustizieri ML, Mascia F, Frezzolini A, De Pità O, Chinni LM, Giannetti A et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 2001;107:871-7.
97. Boniface K, Guignouard E, Pedretti N, Garcia M, Delwail A, Bernard F-X et al. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007;150:407-15.
98. high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation in psoriasis. J Immunol 2005;174:164-73.
99. + regulatory T cells differentiated in vitro from bone-marrow-derived haematopoietic cells of psoriasis patients with a family history of the disorder. Brit J Dermatol 2008;158:298-305.
100. Baker BS, Fry L. Immunotargeting: A biological approach to the treatment of psoriasis. Drug Discovery Today: Ther Strategies 2007;doi:10.1016/j.ddstr. 2007.11.002.
101. Netto EM, Takahashi D, de Fátima Paim de Oliveira M, Barbosa P, Ferraz N, Paixão A et al. Phase II randomised, placebo-controlled trial of M.vaccae-derived protein (PVAC) for the treatment of psoriasis. Vaccine 2006;24:5056-63.
102. Vandenbark AA, Morgan E, Bartholomew R, Bourdette D, Whitham R. Carlo D et al. TCR peptide therapy in human autoimmune diseases. Neurochem Res 2001;26:713-30.